---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-004157"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-02-13T23:59:59+00:00"
generated_at: "2026-05-26T22:12:15.180243+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics Q3 net loss $4.2M; Phase 3 STRIVE-ON meets endpoint; $15M placement

## Summary
- Net loss $4.2M ($0.36/sh) vs $2.4M ($0.21/sh) YoY; R&D $2.2M up from $1.4M on GTx-104 trial.
- Phase 3 STRIVE-ON safety trial met primary endpoint; NDA for GTx-104 anticipated H1 2025.
- Secured $15M upfront private placement (Nantahala Capital, ADAR1, Stonepine); up to $15M additional from warrant exercises.
- Cash at Dec 31, 2024: $11.1M, down from $23.0M at Mar 31, 2024.
- FDA provided guidance on single pivotal trial design for GTx-102 (Ataxia-Telangiectasia) toward NDA.

## SEC filing metadata
- accession: 0001140361-25-004157
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-02-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/0001140361-25-004157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125004157/ef20043203_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-004157
- JSON: https://secwatch.observer/filing/0001140361-25-004157.json
- Plain text: https://secwatch.observer/filing/0001140361-25-004157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.